<SEC-DOCUMENT>0001193125-20-277442.txt : 20201027
<SEC-HEADER>0001193125-20-277442.hdr.sgml : 20201027
<ACCEPTANCE-DATETIME>20201027060300
ACCESSION NUMBER:		0001193125-20-277442
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20201027
FILED AS OF DATE:		20201027
DATE AS OF CHANGE:		20201027

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Opthea Ltd
		CENTRAL INDEX KEY:			0001815620
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39621
		FILM NUMBER:		201261938

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 4
		STREET 2:		650 CHAPEL STREET
		CITY:			SOUTH YARRA, VICTORIA
		STATE:			C3
		ZIP:			3141
		BUSINESS PHONE:		61 3 9826 0399

	MAIL ADDRESS:	
		STREET 1:		LEVEL 4
		STREET 2:		650 CHAPEL STREET
		CITY:			SOUTH YARRA, VICTORIA
		STATE:			C3
		ZIP:			3141
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d52948d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Month of October 2020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-39621</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>OPTHEA LIMITED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level&nbsp;4
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>650 Chapel Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>South Yarra, Victoria 3141 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Australia </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of
principal executive offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form</FONT> <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS REPORT ON FORM <FONT STYLE="white-space:nowrap">6-K</FONT>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;27, 2020, Opthea Limited lodged a press release with the Australian Securities Exchange, or ASX, announcing the receipt of a
A$8.5&nbsp;million research and development (R&amp;D) cash tax incentive from the Australian Taxation Office. A copy of this press release is attached to this report on Form <FONT STYLE="white-space:nowrap">6-K</FONT> as Exhibit 99.1. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBITS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d52948dex991.htm">Press Release dated October&nbsp;27, 2020 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>OPTHEA LIMITED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October&nbsp;27, 2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Michael Tonroe</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael Tonroe</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer and Company Secretary</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d52948dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g52948g05t48.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX Release </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">27&nbsp;October
2020 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Opthea Receives A$8.5m R&amp;D Tax Incentive </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Melbourne, Australia; 27&nbsp;October 2020</B> &#150; Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing a novel
therapy to treat highly prevalent and progressive retinal diseases, today announces it has received a A$8.5&nbsp;million research and development (R&amp;D) tax credit from the Australian Taxation Office. The cash incentive is for research and
development costs incurred in the 2019/2020 financial year, and represents the amount disclosed in the company&#146;s audited financial statements at 30&nbsp;June 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The R&amp;D tax incentive credit relates to both Australian and eligible overseas expenditure for the development of Opthea&#146;s lead candidate <FONT
STYLE="white-space:nowrap">OPT-302.</FONT> The R&amp;D Tax Incentive is as an Australian Federal Government program under which companies can receive cash incentives for 43.5% of eligible research and development expenditure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Megan Baldwin, CEO&nbsp;&amp; Managing Director of Opthea commented &#147;This R&amp;D tax incentive credit of A$8.5&nbsp;million further strengthens our
balance sheet as Opthea prepares to initiate patient recruitment into pivotal Phase 3 clinical trials of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in wet AMD early in 2021.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Opthea </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Opthea (ASX:OPT) is a biopharmaceutical
company developing a novel therapy to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration (wet AMD) and diabetic macular
edema (DME). Opthea&#146;s lead product candidate <FONT STYLE="white-space:nowrap">OPT-302</FONT> is being developed for use in combination with <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> monotherapies to achieve broader inhibition of the
VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting <FONT STYLE="white-space:nowrap">VEGF-A</FONT> alone. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Inherent risks of Investment in Biotechnology Companies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is
designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent
applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea
are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and
manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statements in this announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995. Any statement describing Company goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an <FONT STYLE="white-space:nowrap">at-risk</FONT> statement, including, but not limited to, the
initiation of patient recruitment for Opthea&#146;s planned pivotal Phase 3 clinical trials of <FONT STYLE="white-space:nowrap">OPT-302</FONT> in wet AMD. Such statements are based on Opthea&#146;s current plans, objectives, estimates, expectations
and intentions and are subject to certain risks and uncertainties, including risks and uncertainties associated with clinical trials and product development and the impact of general economic, industry or political conditions in Australia, the
United States or internationally. These and other risks and uncertainties are described more fully in the section titled &#147;Risk Factors&#148; in the final prospectus filed with the SEC on October&nbsp;19, 2020. The Company undertakes no
obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements as
predictions of future events, which statements apply only as of the date of this announcement. Actual results could differ materially from those discussed in this ASX announcement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Authorized for release to ASX by Megan Baldwin, CEO&nbsp;&amp; Managing Director </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B><I>Company&nbsp;&amp; Media Enquiries:</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B><I>Join our email database to receive program updates:</I></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Megan Baldwin, PhD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Tel: +61 (0) 3 9826 0399</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CEO&nbsp;&amp; Managing Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">info@opthea.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Opthea Limited</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">www.opthea.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tel: +61 (0) 447 788 674</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>megan.baldwin@opthea.com</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B><I>Australia:</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B><I>U.S.A. &amp; International:</I></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Rudi Michelson</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Jason Wong</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Monsoon Communications</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Blueprint Life Science Group</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Tel: +61 (0) 3 9620 3333</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Tel: +1 415 375 3340, Ext 4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Jwong@bplifescience.com</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g52948g05t48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g52948g05t48.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M_5N,-_\ 7_"N&I0G2W1Z-'%4JWPO4U\UB=04 % !0 4 % !0 4 % !0 4 %
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MMM[GJ0IPIJT%9$PXI%A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
/!0 4 % !0 4 % !0!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
